We have more trials planned for lung cancer, pancreatic cancer, ovarian cancer and breast cancer.

In fact, one in 70 women will be diagnosed with ovarian cancer.

So this is a woman, 46 years old, who had recurrent lung cancer.

Uganda's recurrent expenditure by recurrent what do I mean?

It is just your regular protein unless you have pancreatic, ovarian, or lung cancer.

In the next month, the end of December, you'll see ovarian cancer, and then lung cancer will come several months after.

She comes back three years later at age 42 with more ovarian cancer, more chemotherapy.

Recently, I developed a novel paper sensor for the detection of pancreatic, ovarian, and lung cancer.

Recently, I developed a novel paper sensor for the detection of pancreatic, ovarian and lung cancer.

Recently, I've developed a novel paper sensor for the detection of pancreatic, ovarian and lung cancer.

Also, the protein I am detecting, called mesothelin, it is overexpressed in both ovarian and lung cancer.

It is essentially your ordinary run of the mill protein unless you have pancreatic, ovarian, or lung cancer.

Two years later, she comes back with stage 3C ovarian cancer, unfortunately treated again with surgery and chemotherapy.

So we wanted to figure out how these ovarian cancer cells are becoming resistant to this drug called Cisplatin.

So, if you can detect this protein, then you can potentially detect pancreatic, ovarian, and lung cancer on the earlier stages.

Cisplatin is a relatively common ovarian cancer chemotherapy drug a relatively simple molecule made in the lab that messes with the DNA of cancer cells and causes them to kill themselves.

We've run a phase two trial in Switzerland on, again, recurrent patients patients who have received standard therapy and whose cancer has come back.

So ovarian cancer is one of those cancers that most people don't know about, or at least don't pay that much attention to.

And that our hearts will be rid of that one disease burden that comes from pancreatic, ovarian and lung cancer, and potentially any disease.

But, eventually at the end, I ended up with one small paper sensor that could detect pancreatic, ovarian, and lung cancer with 100 percent accuracy.

It's just, how do we make that recurrent and scale it?

Cancer

Cancer?

Cancer.

Cancer.

Cancer.

Cancer.

And so in the next two to five years, this sensor could potentially lift the pancreatic cancer survival rates from a dismal 5.5 percent to close to 100 percent, and it would do similar for ovarian and lung cancer.

Novocure conducted its first phase three randomized trial in patients with recurrent GBM.

HOW? Cancer.

Lung cancer.

Lung cancer?

For cancer?

The cancer?

From cancer?

The cancer.

I guess my cancer different from your cancer.

The first cancer was done, which was brain cancer.

Mesothelin is just your ordinary run of the mill type of protein, unless you have pancreatic, ovarian, or lung cancer, in which case, it is found at these greatly increased levels.

I think we have found the problem. Your ovarian follicles are still immature.

Cancer took him.

You have cancer.

You have cancer.

Tropic of Cancer

Yes, breast cancer.